Since the first allogeneic hematopoietic stem cell transplantation (HCT) was performed by
Dr. E. Donnall Thomas in 1957, the field has advanced with new stem cell sources, immune …

Matching for the major histocompatibility complex (MHC)—and more specifically, the human
leukocyte antigen (HLA) system—has been the gold standard in transplantation for decades …

Recently, novel strategies to control graft‐versus‐host disease and facilitate engraftment
have allowed an increasing number of human leukocyte antigen (HLA)‐haploidentical …

Allogeneic hematopoietic cell transplantation (HCT) can cure patients with various
hematologic diseases. The major benefit of allogeneic HCT depends on the graft-versus …

Introduction: Allogeneic hematopoietic cell transplantation is frequently used to treat
malignant and non-malignant conditions, and many patients lack a human leukocyte antigen …

The number of HLA-haploidentical hematopoietic cell transplants continues to increase
worldwide due to recent improvements in outcomes, allowing more patients with …

Haploidentical hematopoietic stem cell transplantation (HSCT) provides an opportunity for
nearly all patients to benefit from HSCT when a human leukocyte antigen (HLA) …

Only one-fourth of patients with fatal haematological disorders and malignancies will have
an HLA-matched sibling donor to create access to potentially curative allogeneic stem cell …

Haploidentical hematopoietic stem cell transplantation (HSCT) provides an opportunity for
nearly all patients to benefit from HCT when a HLA genotypically matched sibling is not …

Multiple donors are generally available for haploidentical hematopoietic stem cell
transplantation. Here we discuss the factors that should be considered when selecting …